Neptune Technologies (NASDAQ:NEPT)
The Company develops proprietary and potent health ingredients from underexploited marine biomasses, such as krill, with its patented extraction process.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
TMFStockSpam
Recs
They make krill oil capsules. They don't make money. Too speculative in an already too crowded field against better competitors.
Recs
No factory, no product, few employees. Should go to zero. Acasti subsidiary (ACPHF) has a price of 2.15, book value of 0.17, traded last 10 days at 333 shares/day. APO.V, its Canadian symbol, trades more, but its book value is an issue with negative cash flow.
Recs
TMFStockSpam:
caps.fool.com/Pitch/NEPT/5785429/dear-mr-smith-with-the-sec-tak.aspx
Recs
Krill Oil? This is crap.
Recs
Trash stock.
Recs
Recs
Dear Mr. Smith,
With the SEC taking important steps last week to suspend trading of 17 fraudulent penny stocks, much needed action was taken against microcap fraud and certain groups that work with them. An important step in helping investors to make informed choices when it comes to the potentially lucrative, yet volatile nature of penny stocks, believes investment analyst Peter Leeds.
While penny stocks certainly aren’t for everyone, penny stocks can be a valuable part of an investor’s portfolio. Below, Leeds provides his list of the top 5 penny stocks to own this summer, noting all of these companies are fundamentally solid, with great upside. Leeds is available for interview to further discuss these penny stock picks.
Neptune Technologies & Bioresources, Inc.
NEPT (Nasdaq)
Health conscious people often become even more so in the summer. Whether training for the olympics, or just trying to be generally healthy, Neptune can help.
A recognized leader of science based products for the nutraceutical and pharmaceutical markets, Neptune Technologies & Bioresources, Inc. (NEPT) is a profitable company with strong fundamentals, growing revenues, and great momentum.
Recs
new product for world wide market
Recs
This is best in class in a $30 Billion hyperlipidemia drug industry.
Recs
Already making money and more items in the pipeline with little or no side effects. I like this over several years. It's probably hit a ceiling now (3.50), but long term I like it's potential.
Recs
Lots of negativity in the CAPS community on this one, but I will take the other side. I have done well on this in real life and think it still has some room to grow (with obvious risks).
Good bull case here: http://biomedreports.com/2011041365978/neptune-technologies-and-bioresources-presents-significant-value-and-opportunity.html
Recs
damn what a crazy dog
Recs
The wolf pack has arrived
Recs
meds a big buss
Recs
I expect the stock to be overall stagnant (yet fluctuating) for awhile, but to eventually have some nice growth once benefits are more widely known. Already studies support use for hyperlipidemia (lowers bad LDL cholesterol while raising good HDL cholesterol), ADHD, PMS, arthritis/aches/pains/inflammation (significantly reduces CRP markers), and skin health. This is despite some of the studies using tiny doses which are only 1/4th the amount that is in the product serving (which is two very small gelcaps or capliques).
Here are some supporting studies that I have bookmarked (there are more besides these actually) : http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17353582&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum , http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15656713&ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum , and http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=12777162&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
Doctor Mike give a good overall summary of it's pain relieving effects at http://www.proteinpower.com/drmike/uncategorized/why-krill-oil/
It has been shown to be significantly more effective than fish oil for controlling hyperlipidemia. The advantages over fish oil (or less advanced krill oils) being it's much better absorbing phospholipid form (rich in choline) and inherent high antioxidant capacity (over 300x greater than vitamin E for instance).
Yeah, right now people hear about krill oil and think "WTF? Must be some marketing garbage." Thus far there hasn't been much of a public promotion (besides press releases that only investors would read). Slowly though word is getting out and major health gurus such as Dr. Mercola, Dr. Weill (such as his featured article in Time Magazine), and Dr. Mike Eades have all recently endorsed krill oil and will likely snowball further exposure. The deal with Yoplait (yogurt) will be able to move foward now that NKO has been given GRAS status in the U.S.A (allowing it to be used in functional food). That would be a huge boon to recognition of NKO.
In summary I'd say this stock definitely has some long term potential (2 to 4 years), meaning the skeptics may want to wait and see if these recent developments (increased exposure) help out the companies thus far lagging finances. Personally I know the stuff works (helped with my mood and knee pains), so I'm no skeptic.
Recs
I almost feel guilty underperforming this company, it's out of this world.
Recs
I don't know anything about this stock, except its symbol. It's hard to imagine a competent management would not notice the way it sounds. (Sound it out: N-ept.)
As a rule, shorting negative-cash-flow companies that issue a lot of stock and are researching technology that may never have a market even if it does pan out, tends to work out ok.
Recs
Look at their financials.... is that a joke?
Not to mention it is a little faddy: krill?
Make more money off of selling them whole to food companies.
Recs
sounds like a fad to me
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 20